Transport in Caco-2 cell monolayers of antidiabetic cucurbitane triterpenoids from Momordica charantia fruits
- PMID: 25116119
- DOI: 10.1055/s-0034-1382837
Transport in Caco-2 cell monolayers of antidiabetic cucurbitane triterpenoids from Momordica charantia fruits
Abstract
Bitter melon, the fruit of Momordica charantia L. (Cucurbitaceae), is a widely-used treatment for diabetes in traditional medicine systems throughout the world. Various compounds have been shown to be responsible for this reputed activity, and, in particular, cucurbitane triterpenoids are thought to play a significant role. The objective of this study was to investigate the gastrointestinal transport of a triterpenoid-enriched n-butanol extract of M. charantia using a two-compartment transwell human intestinal epithelial cell Caco-2 monolayer system, simulating the intestinal barrier. Eleven triterpenoids in this extract were transported from the apical to basolateral direction across Caco-2 cell monolayers, and were identified or tentatively identified by HPLC-TOF-MS. Cucurbitane triterpenoids permeated to the basolateral side with apparent permeability coefficient (P app) values for 3-β-7-β,25-trihydroxycucurbita-5,23(E)-dien-19-al and momordicines I and II at 9.02 × 10(-6), 8.12 × 10(-6), and 1.68 × 10(-6)cm/s, respectively. Also, small amounts of these triterpenoids were absorbed inside the Caco-2 cells. This is the first report of the transport of the reputed antidiabetic cucurbitane triterpenoids in human intestinal epithelial cell monolayers. Our findings, therefore, further support the hypothesis that cucurbitane triterpenoids from bitter melon may explain, at least in part, the antidiabetic activity of this plant in vivo.
Georg Thieme Verlag KG Stuttgart · New York.
Similar articles
-
Identification of chemotypes in bitter melon by metabolomics: a plant with potential benefit for management of diabetes in traditional Chinese medicine.Metabolomics. 2019 Jul 18;15(8):104. doi: 10.1007/s11306-019-1565-7. Metabolomics. 2019. PMID: 31321563
-
Two new cucurbitane triterpenoids from the seeds of Momordica charantia.J Asian Nat Prod Res. 2014;16(5):476-82. doi: 10.1080/10286020.2014.914502. Epub 2014 Apr 29. J Asian Nat Prod Res. 2014. PMID: 24773084
-
Cucurbitane Triterpenoids from the Fruits of Momordica Charantia Improve Insulin Sensitivity and Glucose Homeostasis in Streptozotocin-Induced Diabetic Mice.Mol Nutr Food Res. 2018 Apr;62(7):e1700769. doi: 10.1002/mnfr.201700769. Epub 2018 Mar 12. Mol Nutr Food Res. 2018. PMID: 29405623
-
Multidimensional Uses of Bitter Melon (Momordica charantia L.) Considering the Important Functions of its Chemical Components.Curr Org Synth. 2025;22(4):516-530. doi: 10.2174/0115701794285586240523101245. Curr Org Synth. 2025. PMID: 40420786 Review.
-
Bitter melon: a panacea for inflammation and cancer.Chin J Nat Med. 2016 Feb;14(2):81-100. doi: 10.1016/S1875-5364(16)60002-X. Chin J Nat Med. 2016. PMID: 26968675 Free PMC article. Review.
Cited by
-
Bitter Melon Extract Yields Multiple Effects on Intestinal Epithelial Cells and Likely Contributes to Anti-diabetic Functions.Int J Med Sci. 2021 Feb 24;18(8):1848-1856. doi: 10.7150/ijms.55866. eCollection 2021. Int J Med Sci. 2021. PMID: 33746602 Free PMC article.
-
Therapeutic Potential of Momordicine I from Momordica charantia: Cardiovascular Benefits and Mechanisms.Int J Mol Sci. 2024 Sep 29;25(19):10518. doi: 10.3390/ijms251910518. Int J Mol Sci. 2024. PMID: 39408847 Free PMC article. Review.
-
Antistress and anti-aging activities of Caenorhabditis elegans were enhanced by Momordica saponin extract.Eur J Nutr. 2021 Jun;60(4):1819-1832. doi: 10.1007/s00394-020-02338-6. Epub 2020 Aug 29. Eur J Nutr. 2021. PMID: 32860532
-
The adjuvant value of Andrographis paniculata in metastatic esophageal cancer treatment - from preclinical perspectives.Sci Rep. 2017 Apr 12;7(1):854. doi: 10.1038/s41598-017-00934-x. Sci Rep. 2017. PMID: 28405006 Free PMC article.
-
Momordicine-I, a Bitter Melon Bioactive Metabolite, Displays Anti-Tumor Activity in Head and Neck Cancer Involving c-Met and Downstream Signaling.Cancers (Basel). 2021 Mar 21;13(6):1432. doi: 10.3390/cancers13061432. Cancers (Basel). 2021. PMID: 33801016 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical